Anti-angiogenic Agents in Ovarian Cancer: Dawn of a New Era?

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Bevacizumab and its use in epithelial ovarian cancer

(2011) Ursula A Matulonis   Future Oncology

Overview of anti-angiogenic agents in development for ovarian cancer

(2011) Robert A. Burger   GYNECOLOGIC ONCOLOGY

Big Costs for Little Gain in Ovarian Cancer

(2011) Martee L. Hensley   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study

(2010) J. J. Biagi et al.   ANNALS OF ONCOLOGY

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab

(2010) M.P. Smerdel et al.   GYNECOLOGIC ONCOLOGY

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

(2009) Ursula A. Matulonis et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Müllerian Tumors

(2009) Richard T. Penson et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

(2009) Noriyuki Katsumata et al.   LANCET

What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule?

(2009) R Scott Braithwaite et al.   MEDICAL CARE

Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

(2007) Agustin A. Garcia et al.   JOURNAL OF CLINICAL ONCOLOGY